PT-141 (Bremelanotide)

PT-141, also known as bremelanotide and marketed as Vyleesi, is a synthetic cyclic heptapeptide derived from Melanotan II. Through targeted modifications, it was made selective for the MC3R and MC4R melanocortin receptors — the receptors that mediate the central nervous system effects on sexual function — while removing the MC1R activity responsible for tanning.

In 2019, PT-141 received FDA approval as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on the RECONNECT phase 3 trial program, which demonstrated statistically significant improvements in desire and reductions in distress versus placebo.

Most clinical and research data is on subcutaneous injection, but nasal spray formulations have grown in research popularity. The nasal route exploits the olfactory and trigeminal pathways for partial CNS uptake, with onset and peak-effect timing that some research subjects find more practical than injection.

PT-141 (later named bremelanotide) was developed at Palatin Technologies in the late 1990s as a deliberately more selective successor to Melanotan II. The Palatin team had been investigating the melanocortin system's role in sexual function and recognized that MT-II's libido and erectile effects came from MC3R and MC4R activation in the brain — separable in principle from the MC1R-mediated pigmentation effects.

Through targeted modifications (notably substitution of the MC1R-binding residues), PT-141 was made meaningfully selective for MC3R and MC4R. Early phase 1 trials demonstrated effects on sexual desire and erectile function without the tanning response characteristic of MT-II.

The first development program targeted male erectile dysfunction with both subcutaneous and intranasal formulations. The intranasal program was halted after observed transient blood pressure elevations in some subjects — leading to the strategic pivot to subcutaneous administration in female sexual dysfunction populations, where the drug proved more efficacious and tolerable.

FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women came in June 2019 under the brand name Vyleesi. It was only the second FDA-approved drug for female sexual dysfunction (after flibanserin) and the first acting on the central melanocortin system.

Despite the original FDA program ending the nasal route, intranasal PT-141 has remained an active area of independent research — the practical advantages (no injection, faster onset, on-demand use) continue to drive interest in formulation work.

PT-141 acts on MC4R (and to a lesser extent MC3R) in the hypothalamus and other CNS regions involved in sexual desire and arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on penile vascular smooth muscle, PT-141 works centrally — affecting desire itself rather than the mechanical response to it.

MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus is the principal locus of effect. Downstream pathways involve dopaminergic neurons in the reward circuitry, providing a neurochemical basis for the increased desire reported by responders.

Because the mechanism is central rather than peripheral, PT-141 can produce desire and arousal independent of vascular function — a meaningful distinction in research populations where PDE5 inhibitors are contraindicated or ineffective.